People with endocrine disorders are at higher risk to develop multiple cardiovascular and renal abnormalities, which on the long-term can lead to end-organ damage and a high prevalence of chronic comorbidities such as hypertension, heart failure, and chronic kidney disease. Poor or delayed diagnosis and the relatively limited therapeutic interventions tailored to end-organ damage are among the challenges that this patient population faces.
The goal of this research topic is to better understand the molecular mechanisms involved in the pathophysiology of cardiovascular and/or renal dysregulation caused by endocrine disorders, highlighting novel therapeutic approaches for preventing, delaying progression or treating this pathology.
The research topic of interest includes therapies aimed at mitigating pathophysiological changes in both the cardiovascular and renal systems caused by a variety of endocrine disorder-related conditions such as diabetic nephropathy, metabolic syndrome, polycystic ovary syndrome, and hyperaldosteronism. Original research, clinical trials, review articles, case reports, and other article types presenting basic and clinical research are encouraged. The subtopics of research include, but are not limited to, the role of the following on the progression of cardiovascular/renal end-organ damage in endocrine disorder diseases:
1. Role of sex hormones in cardiovascular/renal disorders associated with endocrine diseases.
2. Sex differences in the pathophysiological changes in the renal and cardiovascular systems associated with endocrine disorders.
3. Immunomodulatory approaches in the cardiorenal dysfunction associated with endocrine disorders.
4. Prevalence and mechanisms of cardiorenal dysregulation in Transgender population, as well as animal models of gender affirming hormonal therapy.
5. Oxidative stress and the potential role of direct versus indirect antioxidants in controlling cardiorenal dysregulation in endocrine diseases.
6. Aging as a risk factor for cardiorenal dysfunction in endocrine disorder patients and animal models.
7. The impact of maternal/paternal endocrine disorders on offspring cardiovascular and renal health, as well as potential therapeutic interventions
People with endocrine disorders are at higher risk to develop multiple cardiovascular and renal abnormalities, which on the long-term can lead to end-organ damage and a high prevalence of chronic comorbidities such as hypertension, heart failure, and chronic kidney disease. Poor or delayed diagnosis and the relatively limited therapeutic interventions tailored to end-organ damage are among the challenges that this patient population faces.
The goal of this research topic is to better understand the molecular mechanisms involved in the pathophysiology of cardiovascular and/or renal dysregulation caused by endocrine disorders, highlighting novel therapeutic approaches for preventing, delaying progression or treating this pathology.
The research topic of interest includes therapies aimed at mitigating pathophysiological changes in both the cardiovascular and renal systems caused by a variety of endocrine disorder-related conditions such as diabetic nephropathy, metabolic syndrome, polycystic ovary syndrome, and hyperaldosteronism. Original research, clinical trials, review articles, case reports, and other article types presenting basic and clinical research are encouraged. The subtopics of research include, but are not limited to, the role of the following on the progression of cardiovascular/renal end-organ damage in endocrine disorder diseases:
1. Role of sex hormones in cardiovascular/renal disorders associated with endocrine diseases.
2. Sex differences in the pathophysiological changes in the renal and cardiovascular systems associated with endocrine disorders.
3. Immunomodulatory approaches in the cardiorenal dysfunction associated with endocrine disorders.
4. Prevalence and mechanisms of cardiorenal dysregulation in Transgender population, as well as animal models of gender affirming hormonal therapy.
5. Oxidative stress and the potential role of direct versus indirect antioxidants in controlling cardiorenal dysregulation in endocrine diseases.
6. Aging as a risk factor for cardiorenal dysfunction in endocrine disorder patients and animal models.
7. The impact of maternal/paternal endocrine disorders on offspring cardiovascular and renal health, as well as potential therapeutic interventions
